98%
921
2 minutes
20
Dynamic control of gene expression is critical for blood stage development of malaria parasites. Here, we used multi-omic analyses to investigate transcriptional regulation by the chromatin-associated microrchidia protein, MORC, during asexual blood stage development of the human malaria parasite . We show that MORC (PF3D7_1468100) interacts with a suite of nuclear proteins, including APETALA2 (ApiAP2) transcription factors (AP2-G5, AP2-O5, AP2-I, PF3D7_0420300, PF3D7_0613800, PF3D7_1107800, and PF3D7_1239200), a DNA helicase DS60 (PF3D7_1227100), and other chromatin remodelers (CHD1 and EELM2). Transcriptomic analysis of MORC knockdown parasites revealed 163 differentially expressed genes belonging to hypervariable multigene families, along with upregulation of genes mostly involved in host cell invasion. In vivo genome-wide chromatin occupancy analysis during both trophozoite and schizont stages of development demonstrates that MORC is recruited to repressed, multigene families, including the genes in subtelomeric chromosomal regions. Collectively, we find that MORC is found in chromatin complexes that play a role in the epigenetic control of asexual blood stage transcriptional regulation and chromatin organization.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483127 | PMC |
http://dx.doi.org/10.7554/eLife.92201 | DOI Listing |
Acta Parasitol
September 2025
Facultad de Ciencias Agropecuarias, Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico.
Purpose: Taenia pisiformis cysticerci have been reported in the female reproductive tract of rabbits, and this parasitosis is known to alter reproductive behavior and reduce embryo implantation; however, tissue-based studies relating the immune system to the implantation site during infection have not been previously addressed. Therefore, our research provides new information on the interaction between pregnancy and parasitic infection.
Methods: This study evaluated the recruitment of immune cells in uterine tissue during T.
Khirurgiia (Mosk)
September 2025
Mogilev Regional Clinical Hospital, Mogilev, Republic of Belarus.
Objective: To evaluate clinical and laboratory effectiveness of ultrasound treatment for purulent wounds.
Material And Methods: The study enrolled 46 patients with purulent wounds divided into the main group (23 patients, ultrasonic treatment) and the control group (23 patients, traditional treatment). We assessed treatment effectiveness considering visual data, quality of granulation tissue, wound defect area and marginal epithelialization, complete blood count and C-reactive protein.
Nurs Res
September 2025
College of Nursing & Institute of Nursing Research, Korea University, Seoul, South Korea.
Background: Existing research fails to address the complex nature of nonspecific chronic lower back pain (cLBP ) despite its detrimental effect on economic, societal, and medical expenditures.
Objectives: We developed a nurse-led, mobile-delivered self-management intervention-Problem-Solving Pain to Enhance Living Well (PROPEL-M)-and evaluated its usability, feasibility, and initial efficacy for South Korean adults with nonspecific cLBP.
Methods: This study was composed of two phases: (a) lab and field usability testing for a gamified mobile device application; and (b) a pilot study employing a one-arm pre-test and post-test design among adults aged 18-60 years with nonspecific cLBP.
Background: Based on the widespread use of the systemic immune-inflammation index (SII), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and lymphocyte-monocyte ratio (LMR), markers, we aimed to calculate and compare the reference intervals (RIs) of these indices in adults, using both nonparametric method according to the Clinical and Laboratory Standards Institute's (CLSI) EP28-A3C:2010 guideline and refineR algorithm using a large dataset.
Methods: We analyzed data from 293,585 adults (18 - 65 years) retrospectively obtained from complete blood count results (using laboratory information system). The study involved a two-stage outlier exclusion process.
Purpose: WU-KONG1B (ClinicalTrials.gov identifier: NCT03974022) is a multinational phase II, dose-randomized study to assess the antitumor efficacy of sunvozertinib in pretreated patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor () exon 20 insertion mutations (exon20ins).
Methods: Eligible patients with advanced-stage exon20ins NSCLC were randomly assigned by 1:1 ratio to receive sunvozertinib 200 mg or 300 mg once daily (200 and 300 mg-rand cohorts).